Catalent ($CTLT) has a deal to pick up a California company that specializes in early phase drug development and clinical supply manufacturing, adding spray drying technology to Catalent's capabilities in the process.
The Somerset, N.J.-based drug services company today said it has a deal to buy Pharmatek Laboratories. Catalent said the San Diego-based Pharmtek handles development of oral, injectable and topical products and has a facility that comprises 68,000 square feet of laboratory, manufacturing and support space, including 18,000 square feet dedicated to development and manufacturing of highly-potent compounds.
Catalent says the deal will add spray drying to Catalent’s portfolio of drug formulation and delivery technologies. Pharmatek earlier this summer expanded its spray-drying capacity. Catalent also is adding Pharmatek’s 200 employees to its operations. The two companies did not disclose the price for the deal, which it said it expects to close in a few weeks.
A number of companies have been adding spray-drying capabilities or capacity for highly potent drugs which generally have poor water solubility. Portuguese contract manufacturer Hovione last year expanded its spray drying at a facility in New Jersey while Capsugel last year completed a $25 million spray-drying project at its facility in Bend, OR.
Yesterday, Madrid, Spain-based API maker Suanfarma, announced it had invested in Idifarma. The Pamplona, Spain-based Idifarma specializes in high potency development and manufacturing and spray drying.
- here’s the release